Product Code: RP-ID-10246008 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10246008
Market Overview:
Global Atopic Dermatitis (AD) Market: Analysis By Therapy (Biologic, Oral, Topical, Photo), End User, Pipeline, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024) 2022-2030
" By the end of 2021, the global atopic dermatitis market is estimated to be valued at ~USD 12 billion, thereby marking a CAGR of more than 15% over the period 2022-2030. Rising pollution levels, accelerating urbanization, unhealthy lifestyles, and the increase in the number of allergies supported by hygiene assumptions are factors that contribute to the higher global prevalence of atopic dermatitis. It is the most common form of eczema and there is no permanent cure, but new treatments are being introduced on the market to control the itching and discomfort
associated with AD. Topical therapy is the highlight of the AD market because it is easy to apply on the skin and has better results. However, with the emergence of the first Dupixent targeted biological therapy (a cooperation between Sanofi and Regeneron) in major regions of the world in 2017, the revenue of the AD market has increased significantly and is expected to increase exponentially during the forecast period .
In addition, the atopic dermatitis market is also expected to grow due to the well-designed product portfolio of pharmaceutical companies. In addition, since the number of patient visits for AD, asthma, allergies, and hay fever is expected to increase during the prognosis period, end-user hospitals may experience peak growth.
Among these regions, the Asia-Pacific region, followed by the Americas and Europe, will have the highest growth rate due to the increase in the prevalence and per capita expenditure of medical care. Report Scope This report analyzes the atopic dermatitis market by treatment segment (biological treatment, topical treatment, oral treatment, phototherapy).
The report assesses the atopic dermatitis market by end users (hospitals, clinics, research laboratories). The global atopic dermatitis market has been analyzed by region (Americas, Europe, Asia Pacific, rest of the world) and country (United States, Canada, Mexico, Brazil, Germany, United Kingdom, Japan, China, India, Australia).
The key insights of the report have been presented through the SWOT framework and market attractiveness charts. Regions, treatments, and end users have already proposed market appeal. In addition, the report analyzes the main opportunities, trends, driving factors and challenges of the industry. The report analyzed in detail the drugs being developed to treat atopic dermatitis. Acquisition and development of new products.
The companies analyzed in the report include Sanofi, Regeneron, Pfizer, Allergan, AbbVie, Leo Pharmaceuticals, Eli Lilly, Aclaris, Anaptys Bio, Dermira. The report introduces the historical period and forecast period from 2014 to 2030. Market analysis of atopic dermatitis.
MAIN TARGET AUDIENCES :
Pharmaceutical companies, consulting companies, medical professionals, regulatory agencies. "
Sanofi, Regeneron, Pfizer, Allergan, Abbvie, Leo Pharma, Lilly, Aclaris, Anaptys Bio, Dermira
Related Reports
Proof of Quality & Reliability
